Nexien Biopharma Valuation
| NXEN Stock | USD 0.01 0.01 25.00% |
Nexien Biopharma seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Nexien Biopharma from analyzing the firm fundamentals such as Current Valuation of 2.58 M, shares owned by insiders of 54.17 %, and Return On Equity of -40.7 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Nexien Biopharma's price fluctuation is out of control at this time. Calculation of the real value of Nexien Biopharma is based on 3 months time horizon. Increasing Nexien Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Nexien Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Nexien Pink Sheet. However, Nexien Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.015 | Real 0.0123 | Hype 0.02 | Naive 0.0186 |
The intrinsic value of Nexien Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Nexien Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Nexien Biopharma helps investors to forecast how Nexien pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Nexien Biopharma more accurately as focusing exclusively on Nexien Biopharma's fundamentals will not take into account other important factors: Nexien Biopharma Total Value Analysis
Nexien Biopharma is now forecasted to have valuation of 2.58 M with market capitalization of 1.95 M, debt of 221.73 K, and cash on hands of 116.9 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Nexien Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.58 M | 1.95 M | 221.73 K | 116.9 K |
Nexien Biopharma Asset Utilization
One of the ways to look at asset utilization of Nexien is to check how much profit was generated for every dollar of assets it reports. Nexien Biopharma secures a negative usage of assets of -5.99 %, losing $0.0599 for each dollar of assets held by the firm. Inadequate asset utilization conveys that the company is being less effective with each dollar of assets it secures. Strictly speaking, asset utilization of Nexien Biopharma shows how discouraging it operates for each dollar spent on its assets.Nexien Biopharma Ownership Allocation
Nexien Biopharma maintains a total of 62.77 Million outstanding shares. Nexien Biopharma holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Nexien Biopharma Profitability Analysis
Net Loss for the year was (626.36 K) with profit before overhead, payroll, taxes, and interest of 0.About Nexien Biopharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Nexien Biopharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Nexien Biopharma based exclusively on its fundamental and basic technical indicators. By analyzing Nexien Biopharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Nexien Biopharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Nexien Biopharma. We calculate exposure to Nexien Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Nexien Biopharma's related companies.Nexien BioPharma, Inc. operates as a pharmaceutical company. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien Biopharma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
8 Steps to conduct Nexien Biopharma's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Nexien Biopharma's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Nexien Biopharma's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Nexien Biopharma's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Nexien Biopharma's revenue streams: Identify Nexien Biopharma's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Nexien Biopharma's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Nexien Biopharma's growth potential: Evaluate Nexien Biopharma's management, business model, and growth potential.
- Determine Nexien Biopharma's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Nexien Biopharma's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Nexien Biopharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 60.5 M | |
| Retained Earnings | -10.9 M |
Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.